Baricitinib 4 milligrams (mg) administered orally once daily throughout the 24 month treatment period. Placebo administered orally to maintain blind.
Participants may continue to receive the background non-investigational, open-label conventional disease-modifying antirheumatic drugs (cDMARD), nonsteroidal anti-inflammatory drug (NSAID), corticosteroid, and other analgesic therapies they were receiving at completion of the originating study.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01885078?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
